Hepatocellulcar Carcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Hepatocellulcar Carcinoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 2

NCT07501351

Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of Firs…

Although immunotherapy-based therapies (including targeted-immunotherapy or dual-immunotherapy protocols) have become the first-line standard treatment for adva…

China80 participantsStarted 2026-01-05

Treatment: Intensified Therapy, Conversion Therapy

RecruitingPhase 2

NCT07238881

Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment

While immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), th…

China30 participantsStarted 2025-11-05

Treatment: Dalpiciclib Isetionate Tablets, Dalpiciclib Isetionate Tablets

All recent trials (3 shown)

CompletedNot Applicable

NCT07537985

Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failur…

There is no definitive evidence regarding the therapeutic efficacy of PD-1 inhibitors combined with tyrosine kinase inhibitors (TKIs) after disease progression…

China200 participantsStarted 2020-01-01

Treatment: Lenvatinib, Regorafenib